New Issue: Orbital Catastrophe Ahead? Read Now

The Medication Munchies Mystery

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Antipsychotic drugs have alleviated the debilitating symptoms of thousands of patients with schizophrenia and bipolar disorder, but often at a high price. These drugs can also trigger excessive weight gain, leading to life-threatening complications such as diabetes or heart disease. Now scientists at Johns Hopkins University have uncovered the mechanism by which these drugs stimulate the appetite—a finding that could lead to new agents without the side effect of constant hunger.

Neuroscientists Solomon H. Snyder and Sangwon Kim found that when they administered clozapine, a powerful antipsychotic, to mice, the animals experienced a spike of the appetite-stimulating enzyme AMPK. Then they discovered that blocking a receptor for histamine caused a boost in AMPK similar to the effects of clozapine. Histamine, well known for causing allergy symptoms, has been long suspected to play a role in weight control, but the mechanism has been unknown. The researchers confirmed their finding by administering clozapine to mice genetically engineered to lack the histamine receptor, and these rodents showed no increase in AMPK.

“This is the first time histamine and AMPK have been linked,” Kim says. By blocking histamine receptors, clozapine and other antipsychotics prevent cells from receiving the body's signal to turn off AMPK production. As a result, AMPK builds up in the hypothalamus and continues to stimulate appetite, even when enough food has been consumed. He suggests that pharmaceutical companies may be able to screen out antipsychotic drugs with antihistamine properties and thereby avoid the side effects of weight gain. The researchers say their work may also lead to safer weight-loss drugs.

About Karen Schrock

Kate Schrock has been an editor of Scientific American MIND since 2007, where she edits feature articles and runs Head Lines, the magazine's news department. After studying astronomy and physics at the University of Southern California, she worked in the Laboratory of Neuro Imaging at the University of California, Los Angeles, studying the brain structure of people with schizophrenia. She then enrolled in the Science, Health and Environmental Reporting program at New York University, where she earned a master's degree in journalism.

More by Karen Schrock
SA Mind Vol 18 Issue 2This article was published with the title “The Medication Munchies Mystery” in SA Mind Vol. 18 No. 2 (), p. 11
doi:10.1038/scientificamericanmind0407-11b

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe